search
Back to results

Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.

Primary Purpose

Infection, Fungal

Status
Completed
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Cumin seed extract
clotrimazole
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infection, Fungal

Eligibility Criteria

18 Years - 49 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Women were 18-49 years old and were married;
  2. They had not used antibiotics, immunosuppressive drugs, or vaginal drugs 14 days before the study;
  3. They did not suffer from trichomonal vaginitis, bacterial vaginitis, or cervicitis based on direct smear;
  4. Candidiasis culture was in agreement with clinical symptoms and patient's complaints.

Exclusion Criteria:

  1. Pregnant and lactating women;
  2. Those who had abnormal uterine bleeding;
  3. Women with diabetes or autoimmune diseases;
  4. Women refuse to participate in the study.

Sites / Locations

  • Assiut University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Cumin seed extract

clotrimazole

Arm Description

Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.

Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.

Outcomes

Primary Outcome Measures

The percentage of patients with complete cure
cure is defines as absence of symptoms

Secondary Outcome Measures

Full Information

First Posted
December 23, 2016
Last Updated
June 7, 2020
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT03005353
Brief Title
Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.
Official Title
Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
March 1, 2018 (Actual)
Primary Completion Date
October 31, 2019 (Actual)
Study Completion Date
January 31, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fungal infections have increased over the last two decades, largely because of the increasing size of the population at risk, including patients who are immunocompromised, broad-spectrum antibiotics and intravascular catheter users. Essential oils and other extracts of plants have evoked interest as sources of natural products. They have been shown to possess antibacterial, antifungal, antiviral, insecticidal and antioxidant properties. To the best of our knowledge, no study has examined the efficacy of cumin seed extract on relieving vulvovaginal candidiasis in vivo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection, Fungal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
100 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cumin seed extract
Arm Type
Experimental
Arm Description
Group A (study group) will receive Cumin seed extract vaginal suppositories once daily for 7 days.
Arm Title
clotrimazole
Arm Type
Active Comparator
Arm Description
Group B will receive conventional clotrimazole vaginal suppositories once daily for 7 days.
Intervention Type
Drug
Intervention Name(s)
Cumin seed extract
Intervention Description
patients will receive the drug in suppository form
Intervention Type
Drug
Intervention Name(s)
clotrimazole
Intervention Description
patients will receive the drug in suppository form
Primary Outcome Measure Information:
Title
The percentage of patients with complete cure
Description
cure is defines as absence of symptoms
Time Frame
one week

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women were 18-49 years old and were married; They had not used antibiotics, immunosuppressive drugs, or vaginal drugs 14 days before the study; They did not suffer from trichomonal vaginitis, bacterial vaginitis, or cervicitis based on direct smear; Candidiasis culture was in agreement with clinical symptoms and patient's complaints. Exclusion Criteria: Pregnant and lactating women; Those who had abnormal uterine bleeding; Women with diabetes or autoimmune diseases; Women refuse to participate in the study.
Facility Information:
Facility Name
Assiut University
City
Assiut
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.

We'll reach out to this number within 24 hrs